Understand the source comparison
FDA Peptide Regulations 2026 Changed: Comparison Table
GLP-1 Compounding (503A) Allowed during shortage Prohibited after April 2026 delisting Immediate cessation required No compounding of semaglutide/tirzepatide under 503A authority Complete market exit for traditional pharmacies. Only 503B facilities with 'not e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Compounding (503A)
- Allowed during shortage
- Prohibited after April 2026 delisting
- Immediate cessation required
- No compounding of semaglutide/tirzepatide under 503A authority
- Complete market exit for traditional pharmacies. Only 503B facilities with 'not essentially a copy' justification can continue
- Batch Testing Requirement (503B)
- Annual aggregate testing acceptable
- Mandatory per-batch HPLC, MS, sterility verification
- 35–50% cost increase per batch
- In-house lab investment or 10–14 day third-party testing delay
- This is the single most consequential change. Eliminates rapid-turnaround small-batch production economics
- 'Essentially a Copy' Standard
- Loosely enforced, formulation differences accepted
- Strictly enforced, requires documented clinical differentiation
- Warning letters issued within 60 days of non-compliance
- Must prove therapeutic need that FDA-approved product cannot meet
- Raises barrier to entry for any peptide with an approved equivalent. Dosage variations no longer sufficient
- Research Peptide Access
- Unrestricted for 503B-registered facilities
- Same access, but batch testing applies
- Testing costs absorbed, lead times extended
- No restriction on peptides without FDA-approved equivalents
- Research peptides unaffected by GLP-1 enforcement. Compliance burden increased but legal status unchanged
- Enforcement Timeline
- Reactive, typically 6–12 months post-violation
- Proactive, warning letters within 60 days
- Immediate compliance verification required
- Facilities audited quarterly instead of annually
- FDA shifted from oversight to active enforcement. Non-compliance now results in expedited registration suspension